Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy

Author:

Perrone Valentina1ORCID,Dovizio Melania1ORCID,Leogrande Melania1,Tamma Antonella2,Giovannitti Massimo3,Buzzoni Carlotta2,Esposti Luca Degli1ORCID

Affiliation:

1. CliCon S.R.L. Società Benefit, Health Economics & Outcomes Research, Bologna, 40141, Italy

2. Eli Lilly Italy S.P.A., Sesto Fiorentino, 50019, Italy

3. Eli Lilly Italy S.P.A., Roma, 00144, Italy

Abstract

Aim: Italian real-world analysis of CDK4/6 inhibitor (CDK4/6i) treatment in HR+/HER2- metastatic breast cancer aimed at evaluating patients' medical history, treatment duration, treatment patterns (combination with endocrine therapy), line of therapy and drug dose variations. Materials & methods: CDK4/6i treatment was analyzed using healthcare administrative databases covering 18% of Italians between January 2017 and June 2022. Results: Among CDK4/6i-treated women, palbociclib and abemaciclib (were more frequently combined with fulvestrant, while ribociclib with aromatase inhibitors. CDK4/6i recommended doses were initiated in 72–90% patients and maintained after 3–6 months in respectively 65–57% women. Frontline CDK4/6i use grew over time (reaching 90%). Median time-to-treatment discontinuation was 11.0 months in palbociclib, 15.9 in abemaciclib and 15.4 in ribociclib cohorts. Conclusion: CDK4/6i plus endocrine therapy is increasingly utilized as first-line therapy, with low proportions of dose reductions within 6 months and discontinuations at 1 year.

Publisher

Future Medicine Ltd

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference59 articles.

1. World Health Organization. Breast cancer (2021). https://www.who.int/news-room/fact-sheets/detail/breast-cancer (Accessed 20 April 2023).

2.

Epidemiological characteristics of and risk factors for breast cancer in the world

3. Breast cancer risk factor evaluation in a Western Himalayan state: A case–control study and comparison with the Western World

4. AIOM. I numeri del cancro in Italia (2022). https://www.aiom.it/wp-content/uploads/2022/12/2022_AIOM_NDC-web (Accessed 20 April 2023).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3